You are here

Article Text

Article menu

Download PDFPDF

Poster/ePoster Sessions
06. Ovarian cancer
#62 MicroRNA 1181 and 4314 as promising biomarkers for epithelial ovarian cancer diagnosis and prognosis
Free
  1. Yagmur Minareci1,
  2. Naziye Ak2,
  3. Hamdullah Sozen3,
  4. Ozgur Aydin Tosun4,
  5. Canan Kucukgergin5,
  6. Fatih Aydin5,
  7. Ilknur Bingul5,
  8. Yavuz Mehmet Salihoglu3 and
  9. Samet Topuz3
  1. 1Istanbul University, Faculty of Medicine, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Istanbul, Türkiye
  2. 2Istanbul University; Institute of Oncology, Department of Medical Oncology, Istanbul, Turkey
  3. 3Istanbul University, Faculty of Medicine, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Istanbul, Turkey
  4. 4Istanbul Medeniyet University, Goztepe Research and Education Hospital, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Istanbul, Turkey
  5. 5Istanbul University, Faculty of Medicine, Department of Biochemistry, Istanbul, Turkey

Abstract

Introduction/Background Epithelial ovarian cancer (EOC) is the most ominous tumor of gynecological cancers due to its poor early detection rate and unfavorable prognosis. To date, there is no reliable screening method for the diagnosis of ovarian cancer at an early stage. MiRNAs are small non-coding RNA molecules, and their main function is to downregulate gene expression. The present study compared the serum miRNA1181 and miRNA4314 levels in patients with EOC and healthy controls to measure the diagnostic and prognostic value as candidate biomarkers.

Methodology We extracted serum samples from a total of 135 participants (69 patients with EOC and 66 healthy controls) at the Department of Gynecologic Oncology between September 2018 and December 2019. Relative expressions of miRNA1181 and miRNA4314 were measured by quantificational real-time polymerase chain reaction assay (qRT-PCR).

Results Of the 69 patients with EOC, 15 were stage I, four were stage II, 35 were stage III, and 15 were stage IV (according to FIGO classification). The median OS was 31.9 months (range 0.9–42.1) and the median DFS was 20.4 months (range 0.9–39.0)The present study revealed that both serum miRNA 1181 and miRNA 4314 levels in patients with EOC were dramatically increased compared to healthy controls with p<0.001 for each marker. In addition, there was a significant relationship between miRNA 1181 and miRNA 4314 overexpressions and the stage and prognosis of the disease. Finally, patients with high expression levels of miRNA 1181 and miRNA 4314 had significantly shorter survival rates than those with low expression levels.

Conclusion The current study proposed that serum miRNA1181 and miRNA4314 could discriminate the EOC patients from healthy controls. In addition, both miRNA1181 and miRNA4314 may be predictive biomarkers for ovarian cancer prognosis. Further studies are needed to confirm the findings of the present study.

Abstract #62 Figure 1
Abstract #62 Figure 1

On the right (The relative expression levels of miRNA1181 and miRNA 4314 in patients with epithelial ovarian cancer and healthy controls. *p-value is less than 0.001) On the Left: The relative expression levels of a miRNA 1181 and miRNA 4314 in early stage and advanced stage of epithelial ovarian cancer. *p-value is 0.012, **p-value is less than 0.001.

Disclosures We declared that we have no conflict of interest

http://dx.doi.org/10.1136/ijgc-2023-ESGO.505

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.